Last reviewed · How we verify

NCT05030233: P-NAT-BIO

Pilot Study of Nursing Touch and Biobehavioral Stress

Completed NA Results posted Last updated 18 February 2025
What this trial tests

NA trial testing Nurse-Administered Touch Intervention in Prematurity in 19 participants. Completed in 17 May 2022.

Timeline
10 September 2021
Primary endpoint
20 April 2022
17 May 2022

Quick facts

Lead sponsorOhio State University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingnone
Primary purposesupportive care
Enrollment19
Start date10 September 2021
Primary completion20 April 2022
Estimated completion17 May 2022
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Ohio State University

Who can join

Under 10 Days, any sex, with Prematurity or Stress Reaction. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Average Heart Rate -- During Intervention Primary · during intervention or control period, approximately 20 minutes

heart rate in beats per minute will be measured using an external electrocardiogram monitor and averaged over the intervention or control period

GroupValue95% CI
Nurse-Administered Touch Intervention172.6± 10.5
Standard Care168.6± 9.2
Average Heart Rate -- Recovery Primary · recovery, 30 minutes after intervention delivery or control period

heart rate in beats per minute will be measured using an external electrocardiogram monitor and averaged over the intervention or control period

GroupValue95% CI
Nurse-Administered Touch Intervention161.7± 10.0
Standard Care158.6± 8.4
Average High-frequency Heart Rate Variability -- During Caregiving Episode Secondary · during caregiving episode that included either the nurse-administered touch intervention or was delivered as standard care, approximately 20 minutes

Spectral analysis of high-frequency heart rate variability averaged over the episode of caregiving during which infants received either the nurse-administered touch intervention or standard care. Spectral analysis of the high frequency band is a non-linear measure of heart rate variability that quantifies, primarily, parasympathetic nervous system (vagal) tone.

GroupValue95% CI
Nurse-Administered Touch Intervention3.22.1 – 4.8
Standard Care3.22.5 – 4.3
Average High-frequency Heart Rate Variability -- Recovery Secondary · recovery, 30 minutes after caregiving that included either the nurse-administered touch intervention or standard care

Spectral analysis of high-frequency heart rate variability averaged over the 30-minute period following caregiving that included the nurse-administered touch intervention or was delivered as standard care. Spectral analysis of the high frequency band is a non-linear measure of heart rate variability that quantifies, primarily, parasympathetic nervous system (vagal) tone.

GroupValue95% CI
Nurse-Administered Touch Intervention3.02.1 – 5.5
Standard Care3.02.3 – 4.9
Average Frequency of Skin Conductance Responses -- During Caregiving Episode Secondary · during caregiving episode, approximately 20 minutes

Frequency of skin conductance responses will be measured using an external monitor with electrodes attached to the infant's foot and averaged over the caregiving episode that includes either the nurse-administered touch intervention or standard care. Frequency is measured as number of waves per second over the duration of caregiving.

GroupValue95% CI
Nurse-Administered Touch Intervention0.14± 0.05
Standard Care0.14± 0.05
Average Frequency of Skin Conductance Responses -- Recovery Secondary · recovery, 30 minutes after intervention delivery or control period

Frequency of skin conductance responses will be measured using an external monitor with electrodes attached to the infant's foot and averaged over the 30-minute period following the caregiving episode that included either the nurse-administered touch intervention or standard care. Frequency is measured as number of waves per second over the duration of the 30-minute recovery period.

GroupValue95% CI
Nurse-Administered Touch Intervention0.06± 0.04
Standard Care0.06± 0.05

Adverse events — posted to ClinicalTrials.gov

Time frame: Essential nursing care is scheduled to occur every 3 hours in the NICU. Study electrodes were attached to enrolled infants during the caregiving episode preceding the observed caregiving episode during which data collection occurred. Adverse events were documented from the time study electrodes were attached to the infant until the end of the 30-minute recovery period following the observed caregiving episode. Thus, total recording of adverse events was approximately 3.5 hours.. Reporting threshold: 0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Nurse-Administered Touch Intervention
Serious: 0/19 (0%)
Deaths: 0/19
Standard Care
Serious: 0/18 (0%)
Deaths: 0/18
Other adverse events (1 terms — click to expand)

ReactionSystemNurse-Administered Touch I…Standard Care
bradycardia or oxygen desaturationGeneral disorders

Data from ClinicalTrials.gov NCT05030233 adverse events section.

Sponsor's own description

Randomized cross-over clinical trial to determine the effect of a nurse-administered comforting touch intervention on the biobehavioral stress responses of preterm infants hospitalized in the neonatal intensive care unit.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Prematurity

Currently open trials in the same condition.

Other Ohio State University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05030233.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing